Table 1

The incidence rate of PsA development in patients with PsO

Author, year	Population (n=)	Events (n=)	Follow-up	Study type	Incidence rate (IR) per 100 patients-years	Definition of PsA
Faustini et al, 201610*	41	12	1.2	Cohort prospective	24.4	Clinical diagnosis and CASPAR+
Simon et al, 20209*	114	24	2.3	Cohort prospective	9.7	Clinical diagnosis and CASPAR+
Zabotti et al, 20198*	102	6	1.2	Cohort prospective	4.9	Clinical diagnosis and CASPAR+
Elnady et al, 201923	109	9	2	Cohort prospective	4.3	Clinical diagnosis and CASPAR+
Eder et al, 20177	410	57	3.8	Cohort prospective	3.7	Clinical diagnosis and CASPAR+
Eder et al, 201615	433	51	4.1	Cohort prospective	2.7	Clinical diagnosis and CASPAR+
Belman et al, 202125	627	128	7.7	Cohort retrospective	2.7	Clinical diagnosis
Acosta et al, 202224	1719	239	7.3	Cohort retrospective	1.9	Clinical diagnosis and/or CASPAR +
Gisondi et al, 202226	464	51	6.9	Cohort retrospective	1.6	CASPAR+
Balato et al, 202133	285	22	Not reported	Cohort retrospective	/	Clinical diagnosis
Abji et al, 202122	40	16	Not applicable	Case-control	/	CASPAR+
Green et al, 202132	90 189	1409	Not reported	Bayesian network	/	PsA code and GP evaluation

The IRs subdivided for the presence of arthralgia were as follows: Faustini, 2016: PsO without arthralgia=IR 17.4 (5.6–40.5]; PsO with arthralgia=IR 34.3 (13.8–70.7); Zabotti, 2019: PsO without arthralgia=IR 1.34 (0.0–7.5); PsO with arthralgia=IR 10.9 (3.5–25.4); Simon, 2020: PsO without arthralgia=IR 5.9 (2.4–12.2); PsO with arthralgia=IR 12.5 (6.2–22.4).
*Studies including patients with PsO with arthralgia.
IR, incidence rate; PsA, psoriatic arthritis; PsO, psoriasis.